Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
79 hedge funds and large institutions have $114M invested in Adaptimmune Therapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 27 reducing their positions, and 14 closing their positions.
0% more funds holding
Funds holding: 79 → 79 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
2% less capital invested
Capital invested by funds: $116M → $114M (-$1.83M)
2.36% less ownership
Funds ownership: 65.58% → 63.22% (-2.4%)
48% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$633K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$287K |
| 3 |
Renaissance Technologies
New York
|
+$193K |
| 4 |
Millennium Management
New York
|
+$79.5K |
| 5 |
Jane Street
New York
|
+$55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$884K |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$696K |
| 3 |
BlackRock
New York
|
-$612K |
| 4 |
Citigroup
New York
|
-$454K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$440K |
ADAP Hedge Fund Activity: Q4 2023 in Review
79 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q4 2023, worth a combined $114M — down 1.6% from $116M a quarter earlier.
Fund positioning in ADAP was balanced in Q4 2023: 14 funds opened new positions, 14 closed out, 14 added to existing stakes and 27 trimmed.
The largest buyer was Long Focus Capital Management, adding an estimated $633K. The largest seller was Artal Group, exiting entirely with an estimated $884K sold.
- 79 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $114M of Adaptimmune Therapeutics stock for Q4 2023, down 1.6% quarter-over-quarter.
- 14 funds opened new Adaptimmune Therapeutics positions in Q4 2023 and 14 closed out, a net change of 0 holders.
- The largest Adaptimmune Therapeutics buyer in Q4 2023 was Long Focus Capital Management, an estimated $633K added.
- The largest Adaptimmune Therapeutics seller in Q4 2023 was Artal Group, an estimated $884K sold.
Based on aggregated 13F filings for Q4 2023.